SS Innovations International (SSII) Net Income towards Common Stockholders (2016 - 2026)
SS Innovations International recorded quarterly Net Income towards Common Stockholders of -$3.6 million in Q1 2026, down 122.02% quarter-over-quarter from $16.3 million in Q4 2025, and up 36.94% year-over-year from -$2.6 million in Q1 2025.
SS Innovations International's Net Income towards Common Stockholders history runs 11 years deep, the most recent figure standing at -$3.6 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 36.94% year-over-year to -$3.6 million; the TTM figure through Mar 2026 stood at $8.7 million (up 127.59% YoY), while the FY2025 annual figure was $2.6 million, up 113.61% from the prior year.
- Net Income towards Common Stockholders came in at -$3.6 million for Q1 2026 at SS Innovations International, down from $16.3 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $16.3 million in Q4 2025 to a low of -$16.9 million in Q4 2023.
- A 5-year average of -$3.0 million and a median of -$2.8 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders plunged 3620.87% in 2023 and surged 196.59% in 2025, its largest moves.
- SS Innovations International's Net Income towards Common Stockholders stood at -$1.0 million in 2022, then sank by 1541.8% to -$16.9 million in 2023, then gained by 0.21% to -$16.8 million in 2024, then surged by 196.59% to $16.3 million in 2025, then plunged by 122.02% to -$3.6 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$3.6 million, $16.3 million, and -$3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 1.15 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 187,319.30 |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 199.50 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | SS Innovations International | 770.31 Mn | 746.70 Mn | 5.33 Mn | -3.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.58 Mn |
| Dec 31, 2025 | 16.27 Mn |
| Sep 30, 2025 | -3.72 Mn |
| Jun 30, 2025 | -256,691.00 |
| Mar 31, 2025 | -5.68 Mn |
| Dec 31, 2024 | -16.85 Mn |
| Sep 30, 2024 | -6.12 Mn |
| Jun 30, 2024 | -2.93 Mn |
| Mar 31, 2024 | -2.80 Mn |
| Dec 31, 2023 | -16.88 Mn |
| Sep 30, 2023 | -1.22 Mn |
| Jun 30, 2023 | -1.85 Mn |
| Mar 31, 2023 | -2.99 Mn |
| Dec 31, 2022 | -1.03 Mn |
| Sep 30, 2022 | -486,386.00 |
| Jun 30, 2022 | -752,025.00 |
| Mar 31, 2022 | -80,421.00 |
| Dec 31, 2021 | -352,956.00 |
| Sep 30, 2021 | -418,209.00 |
| Jun 30, 2021 | -412,314.00 |
| Mar 31, 2021 | -300,056.00 |
| Dec 31, 2020 | -221,840.00 |
| Sep 30, 2020 | -375,526.00 |
| Jun 30, 2020 | -220,301.00 |
| Mar 31, 2020 | -307,015.00 |
| Dec 31, 2019 | -1.05 Mn |
| Sep 30, 2019 | -1.40 Mn |
| Jun 30, 2019 | -539,000.00 |
| Mar 31, 2019 | -395,481.00 |
| Dec 31, 2018 | -219,137.00 |
| Sep 30, 2018 | -297,272.00 |
| Jun 30, 2018 | -205,509.00 |
| Mar 31, 2018 | -238,404.00 |
| Dec 31, 2017 | -473,964.00 |
| Sep 30, 2017 | -180,067.00 |
| Jun 30, 2017 | -187,376.00 |
| Mar 31, 2017 | -196,315.00 |
| Dec 31, 2016 | -194,840.00 |
| Sep 30, 2016 | -246,866.00 |
| Jun 30, 2016 | -43,242.00 |